{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:48:28Z","timestamp":1788961708002,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"DOI":"10.1186\/s12959-025-00789-7","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:44:29Z","timestamp":1762962269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Direct oral anticoagulants compared to low molecular weight heparin for the treatment of venous thromboembolism among individuals with gastrointestinal cancer: an updated meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Jie","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"1","key":"789_CR1","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1182\/bloodadvances.2021005590","volume":"6","author":"A Mahajan","year":"2022","unstructured":"Mahajan A, Brunson A, Adesina O, Keegan THM, Wun T. The incidence of cancer-associated thrombosis is increasing over time. Blood Adv. 2022;6(1):307\u201320.","journal-title":"Blood Adv"},{"key":"789_CR2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.critrevonc.2017.08.003","volume":"118","author":"A Falanga","year":"2017","unstructured":"Falanga A, Russo L, Milesi V, Vignoli A. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol-Hematol. 2017;118:79\u201383.","journal-title":"Crit Rev Oncol-Hematol"},{"issue":"4","key":"789_CR3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/DCR.0000000000001946","volume":"64","author":"CA Lewis-Lloyd","year":"2021","unstructured":"Lewis-Lloyd CA, Pettitt EM, Adiamah A, Crooks CJ, Humes DJ. Risk of postoperative venous thromboembolism after surgery for colorectal malignancy: a systematic review and meta-analysis. Dis Colon Rectum. 2021;64(4):484\u201396.","journal-title":"Dis Colon Rectum"},{"key":"789_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00595-021-02260-2","author":"NA Theochari","year":"2022","unstructured":"Theochari NA, Theochari CA, Kokkinidis DG, Kechagias A, Lyros O, Giannopoulos S, et al. Venous thromboembolism after esophagectomy for cancer: a systematic review of the literature to evaluate incidence, risk factors, and prophylaxis. Surg Today. 2022. https:\/\/doi.org\/10.1007\/s00595-021-02260-2.","journal-title":"Surg Today"},{"issue":"2","key":"789_CR5","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/jth.15175","volume":"19","author":"T Chiasakul","year":"2021","unstructured":"Chiasakul T, Patell R, Maraveyas A, Carrier M, Zwicker JI. Discordant reporting of VTE in pancreatic cancer: a systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials. J Thromb Haemost. 2021;19(2):489\u2013501.","journal-title":"J Thromb Haemost"},{"issue":"10","key":"789_CR6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.4251\/wjgo.v11.i10.866","volume":"11","author":"A Recio-Boiles","year":"2019","unstructured":"Recio-Boiles A, Veeravelli S, Vondrak J, Babiker HM, Scott AJ, Shroff RT, et al. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. World J Gastrointest Oncol. 2019;11(10):866\u201376.","journal-title":"World J Gastrointest Oncol"},{"issue":"5","key":"789_CR7","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1055\/s-0040-1720975","volume":"121","author":"W Ageno","year":"2021","unstructured":"Ageno W, Vedovati MC, Cohen A, Huisman M, Bauersachs R, Gussoni G, et al. Bleeding with Apixaban and Dalteparin in patients with Cancer-Associated venous thromboembolism: results from the Caravaggio study. Thromb Haemost. 2021;121(5):616\u201324.","journal-title":"Thromb Haemost"},{"issue":"1","key":"789_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/bjh.19414","volume":"205","author":"R Alikhan","year":"2024","unstructured":"Alikhan R, Gomez K, Maraveyas A, Noble S, Young A, Thomas M. Cancer-associated venous thrombosis in adults (second edition): a British society for haematology guideline. Br J Haematol. 2024;205(1):71\u201387.","journal-title":"Br J Haematol"},{"issue":"5","key":"789_CR9","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1177\/1708538120971148","volume":"29","author":"ME Mokadem","year":"2021","unstructured":"Mokadem ME, Hassan A, Algaby AZ. Efficacy and safety of Apixaban in patients with active malignancy and acute deep venous thrombosis. Vascular. 2021;29(5):745\u201350.","journal-title":"Vascular"},{"key":"789_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.thromres.2019.11.007","volume":"185","author":"FI Mulder","year":"2020","unstructured":"Mulder FI, van Es N, Kraaijpoel N, Di Nisio M, Carrier M, Duggal A, et al. Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: results from the Hokusai VTE cancer study. Thromb Res. 2020;185:13\u20139.","journal-title":"Thromb Res"},{"key":"789_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030559","author":"JH Kim","year":"2022","unstructured":"Kim JH, Yoo C, Seo S, Jeong JH, Ryoo BY, Kim KP, et al. A phase II study to compare the safety and efficacy of direct oral anticoagulants versus subcutaneous Dalteparin for cancer-associated venous thromboembolism in patients with advanced upper gastrointestinal, hepatobiliary and pancreatic cancer: PRIORITY. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14030559.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"789_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.36304","volume":"4","author":"DY Chen","year":"2021","unstructured":"Chen DY, Tseng CN, Hsieh MJ, Lan WC, Chuang CK, Pang ST, et al. Comparison between non-vitamin K antagonist oral anticoagulants and low-molecular-weight heparin in Asian individuals with cancer-associated venous thromboembolism. JAMA Netw Open. 2021;4(2):e2036304.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"789_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-022-00399-7","volume":"20","author":"T Rungjirajittranon","year":"2022","unstructured":"Rungjirajittranon T, Owattanapanich W, Chinthammitr Y, Ruchutrakool T, Suwanawiboon B. Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with Gastrointestinal cancer: a systematic review and meta-analysis. Thromb J. 2022;20(1):41.","journal-title":"Thromb J"},{"key":"789_CR14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"789_CR15","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hern\u00e1n MA, Hopewell S, Hr\u00f3bjartsson A, Junqueira DR, J\u00fcni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898. PMID: 31462531.","DOI":"10.1136\/bmj.l4898"},{"key":"789_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/10760296231189282","volume":"29","author":"KS Caroti","year":"2023","unstructured":"Caroti KS, Khorana AA, Becattini C, Lee AYY, Ekbom A, Carrier M, et al. Rivaroxaban versus low-molecular-weight heparins in a broad cohort of patients with cancer-associated venous thromboembolism: an analysis of the OSCAR-US program. Clinical and Applied Thrombosis\/Hemostasis. 2023;29:10760296231189282.","journal-title":"Clinical and Applied Thrombosis\/Hemostasis"},{"issue":"9","key":"789_CR17","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1080\/03007995.2021.1932448","volume":"37","author":"AT Cohen","year":"2021","unstructured":"Cohen AT, Keshishian A, Lee T, Rosenblatt L, Hlavacek P, Sah J, et al. Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer. Curr Med Res Opin. 2021;37(9):1467\u201382.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"789_CR18","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s11239-023-02858-y","volume":"56","author":"T Guan","year":"2023","unstructured":"Guan T, Laguna A, Soares A, Legasto CS, Block S, Saunders IM, et al. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies. J Thromb Thrombolysis. 2023;56(3):439\u201346.","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"789_CR19","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1016\/j.mayocp.2021.04.026","volume":"96","author":"DE Houghton","year":"2021","unstructured":"Houghton DE, Vlazny DT, Casanegra AI, Brunton N, Froehling DA, Meverden RA, et al. Bleeding in patients with gastrointestinal cancer compared with nongastrointestinal cancer treated with apixaban, rivaroxaban, or enoxaparin for acute venous thromboembolism. Mayo Clin Proc. 2021;96(11):2793\u2013805.","journal-title":"Mayo Clin Proc"},{"issue":"21","key":"789_CR20","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2019.34.e160","volume":"34","author":"JH Lee","year":"2019","unstructured":"Lee JH, Oh YM, Lee SD, Lee JS. Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in gastrointestinal and pancreatobiliary cancer. J Korean Med Sci. 2019;34(21):e160.","journal-title":"J Korean Med Sci"},{"issue":"2","key":"789_CR21","doi-asserted-by":"publisher","first-page":"829","DOI":"10.21873\/invivo.11845","volume":"34","author":"JH Kim","year":"2020","unstructured":"Kim JH, Seo S, Kim KP, Chang HM, Ryoo BY, Yoo C, et al. Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in advanced upper gastrointestinal tract and hepatopancreatobiliary cancer. In Vivo. 2020;34(2):829\u201337.","journal-title":"In Vivo"},{"issue":"5","key":"789_CR22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1055\/s-0041-1735194","volume":"122","author":"G Agnelli","year":"2022","unstructured":"Agnelli G, Mu\u00f1oz A, Franco L, Mah\u00e9 I, Brenner B, Connors JM, et al. Apixaban and Dalteparin for the treatment of venous thromboembolism in patients with different sites of cancer. Thromb Haemost. 2022;122(5):796\u2013807.","journal-title":"Thromb Haemost"},{"issue":"20","key":"789_CR23","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","volume":"36","author":"AM Young","year":"2018","unstructured":"Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017\u201323.","journal-title":"J Clin Oncol"},{"key":"789_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jclinepi.2020.10.013","volume":"130","author":"M Safieddine","year":"2021","unstructured":"Safieddine M, Chapelle C, Ollier E, Ferdynus C, Bertoletti L, Mismetti P, et al. Compared to randomized studies, observational studies may overestimate the effectiveness of doacs: a metaepidemiological approach. J Clin Epidemiol. 2021;130:49\u201358.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"789_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12957-024-03341-5","volume":"22","author":"H Zhou","year":"2024","unstructured":"Zhou H, Chen TT, Ye LL, Ma JJ, Zhang JH. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin for thromboprophylaxis after cancer surgery: a systematic review and meta-analysis. World J Surg Oncol. 2024;22(1):69.","journal-title":"World J Surg Oncol"},{"key":"789_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.amjcard.2025.06.022","volume":"254","author":"A Mousavi","year":"2025","unstructured":"Mousavi A, Shojaei S, Rahmati S, Dastjerdi P, Sabri M, Salehi K, et al. Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated thrombosis: a meta-analysis of randomized controlled trials. Am J Cardiol. 2025;254:32\u201341.","journal-title":"Am J Cardiol"},{"issue":"3","key":"789_CR27","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00464-023-10649-y","volume":"38","author":"H Zhou","year":"2024","unstructured":"Zhou H, Ye LL, Zhou JT, Ma FX, Ma JJ, Zhang JH. Direct oral anticoagulants (DOACs) versus low-molecular-weight heparin (LMWH) for extended thromboprophylaxis following major abdominal\/pelvic cancer-related surgery: a systematic review and meta-analysis. Surg Endosc. 2024;38(3):1131\u20138.","journal-title":"Surg Endosc"},{"key":"789_CR28","doi-asserted-by":"crossref","unstructured":"Lee MC, Wu JY, Yu T, Liao CT, Chang WT, Toh HS et al. Clinical Efficacy and Safety of Novel Anticoagulants for the Management of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis. Cardiovascular drugs and therapy. 2024.","DOI":"10.1007\/s10557-024-07620-x"},{"issue":"2","key":"789_CR29","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-8156","volume":"9","author":"X Song","year":"2021","unstructured":"Song X, Liu Z, Zeng R, Shao J, Liu B, Zheng Y, et al. Treatment of venous thromboembolism in cancer patients: a systematic review and meta-analysis on the efficacy and safety of different direct oral anticoagulants (DOACs). Ann Transl Med. 2021;9(2):162.","journal-title":"Ann Transl Med"},{"issue":"1","key":"789_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-021-00319-1","volume":"19","author":"K Wumaier","year":"2021","unstructured":"Wumaier K, Li W, Chen N, Cui J. Direct oral anticoagulants versus low molecular weight heparins for the treatment of cancer-associated thrombosis: a cost-effectiveness analysis. Thromb J. 2021;19(1):68.","journal-title":"Thromb J"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00789-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-025-00789-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-025-00789-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T15:44:30Z","timestamp":1762962270000},"score":1,"resource":{"primary":{"URL":"https:\/\/thrombosisjournal.biomedcentral.com\/articles\/10.1186\/s12959-025-00789-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["789"],"URL":"https:\/\/doi.org\/10.1186\/s12959-025-00789-7","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}